| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.3 | 0.1 |
| Profit before tax | -0.7 | -3.2 |
| Net income | -0.7 | -3.2 |
| EPS (diluted, $ a share) | $-0.08 | $-0.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1898.8% |
|---|---|
| Operating margin | -37.9% |
10-Q filed with the SEC, NASDAQ: LPCN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lipocine Inc.: key numbers
- Share price
- $1.66Close, Nov 16
- Market cap
- $18.4M
- Shares outstanding
- 11.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lipocine Inc.
All →Lipocine CEO Mahesh V. Patel Buys $79.5K of Stock
Mahesh V. Patel, CEO, bought 50,000 shares of Lipocine Inc. at $1.58 to $1.60 a share (average $1.59) in 2 transactions, worth $79.5K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 211,495 (+13.4%).
- Value
- $79.5K
- Shares
- 50,000
- Average price
- $1.59
- Role
- CEO
- Holding change
- +13.4%
- Trade date
- Nov 12, 2026 to Nov 13, 2026
Lipocine Business Update
Lipocine Inc. announced the dosing of the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is expected to enroll approximately 120 participants and incorporates design improvements from a previous Phase 3 trial, with topline results expected in the second half of 2027.
Lipocine Financial Results
Lipocine Inc. reported financial results for the third quarter of 2026, highlighting a net loss of $0.7 million and a cash position of $21.5 million as of September 30, 2026. The company also provided clinical updates, including the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO) in postpartum depression and the approval of TLANDO in Canada.
- Term
- Q3 2026
Lipocine Investor Presentation
Lipocine Inc. has updated its corporate presentation for use in meetings with investors, analysts, and other stakeholders. The presentation was filed as Exhibit 99.1 to the 8-K and provides a strategic overview of the company's business and development pipeline.
Lipocine Regulatory Approval
Lipocine announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males. The product is licensed to Verity Pharmaceuticals, which plans to launch and commercialize the oral therapeutic in the Canadian market by the end of 2026.
- Counterparty
- Health Canada
Lipocine Insider John W. Higuchi Buys $55K of Stock
John W. Higuchi bought 25,007 shares of Lipocine Inc. at $2.15 to $2.23 a share (average $2.20) in 2 transactions, worth $55K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 241,365 (+7.1%).
- Value
- $55K
- Shares
- 25,007
- Average price
- $2.20
- Holding change
- +7.1%
- Trade date
- Sep 29, 2026 to Sep 30, 2026